Setting Clinical Exposure Levels of Concern for Drug-Induced Liver Injury (DILI) Using Mechanistic in vitro Assays
The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
Severe drug-induced liver injury (DILI) remains a major safety issue due to its frequency of occurrence, idiosyncratic nature, poor prognosis, and diverse underlying mechanisms. Numerous experimental approaches have been published to improve human DILI prediction with modest success. A retrospective analysis of 125 drugs (70 = most-DILI, 55 = no-DILI) from the Food and Drug Administration Liver Toxicity Knowledge Base was used to investigate DILI prediction based on consideration of human exposure alone or in combination with mechanistic assays of hepatotoxic liabilities (cytotoxicity, bile salt export pump inhibition, or mitochondrial inhibition/uncoupling). Using this dataset, human plasma Cmax,total ≥ 1.1 µM alone distinguished most-DILI from no-DILI compounds with high sensitivity/specificity (80/73%). Accounting for human exposure improved the sensitivity/specificity for each assay and helped to derive predictive safety margins. Compounds with plasma Cmax,total ≥ 1.1 µM and triple liabilities had significantly higher odds ratio for DILI than those with single/dual liabilities. Using this approach, a subset of recent pharmaceuticals with evidence of liver injury during clinical development was recognized as potential hepatotoxicants. In summary, plasma Cmax,total ≥ 1.1 µM along with multiple mechanistic liabilities is a major driver for predictions of human DILI potential. In applying this approach during drug development the challenge will be generating accurate estimates of plasma Cmax,total at efficacious doses in advance of generating true exposure data from clinical studies. In the meantime, drug candidates with multiple hepatotoxic liabilities should be deprioritized, since they have the highest likelihood of causing DILI in case their efficacious plasma Cmax,total in humans is higher than anticipated.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The threshold was very similar to a recently published threshold of 1.1 μM total plasma C max set as a predictor of hepatotoxicity for a test set of 125 commercial drugs (Shah et al. 2015).”
From Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury (2017) · cites this paper as Shah et al. 2015
In the citing paper
“In concordance with high daily dose, compounds whose total plasma exposure, in particular C max, were greater than 1.1 μM, were associated with DILI from those that were not (Shah et al. 2015).”
From Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury (2017) · cites this paper as Shah et al. 2015
In the citing paper
“Lastly, drug-induced cytotoxicity in hepatic cell lines (Gustafsson et al. 2014; O’Brien et al. 2006; Shah et al. 2015; Xu et al. 2008) or primary-plated hepatocytes (Schadt et al. 2015) has also been associated with human hepatotoxicity, especially when considering dose or exposure (Schadt et al. 2015; Shah et al. 2015).”
From Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury (2017) · cites this paper as Shah et al. 2015
In the citing paper
“This is important since multi-parameter approaches measuring sublethal pathways are often cost-prohibitive, with large screening needs for early discovery support and medicinal chemistry design requirements based on structure toxicity relationships (Shah et al. 2015).”
From Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury (2017) · cites this paper as Shah et al. 2015
In the citing paper
“These data back up similar reports by Shah et al. (2015) who also demonstrated that a C max, total threshold of 1.1 µM was a major driver in distinguishing DILI-positive and DILI-negative compounds (sensitivity/specificity 80/73%).”
From Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury (2017) · cites this paper as Shah et al. 2015
Citations
Cites
Concordance of the toxicity of pharmaceuticals in humans and in animals
Olson, H., Betton, G., Robinson, D., Thomas, K., Monro, A., Kolaja, G., Lilly, P., Sanders, J., Sipes, G., Bracken, W., et al. (2000) · Regulatory Toxicology and Pharmacology · doi:10.1006/rtph.2000.1399 · Cited by 2,050 · cited 1×
“In many instances, animal toxicology studies fail (Olson et al., 2000) to identify adequate margins for potential human DILI risk that are eventually detected in early clinical development trials, eg, CP-724,714 (Feng et al.”
BackgroundImpact of OATP transporters on pharmacokinetics
Kalliokoski, A., & Niemi, M. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00430.x · Cited by 995
Stepan, A. F., Walker, D. P., Bauman, J., Price, D. A., Baillie, T. A., Kalgutkar, A. S., & Aleo, M. D. (2011) · Chemical Research in Toxicology · doi:10.1021/tx200168d · Cited by 698
Self-citationInhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity
Fromenty, B., & Pessayre, D. (1995) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(95)00012-6 · Cited by 665 · cited 1×
“4 mM) can accumulate further in liver mitochondria or lysosomes due to their basic lipophilic structural properties and interfere with these organelle functions independent of active liver transporter uptake (Fromenty and Pessayre, 1995).”
BackgroundMarroquin, L. D., Hynes, J., Dykens, J. A., Jamieson, J. D., & Will, Y. (2007) · Toxicological Sciences · doi:10.1093/toxsci/kfm052 · Cited by 628
Self-citationKakuda, T. N. (2000) · Clinical Therapeutics · doi:10.1016/s0149-2918(00)90004-3 · Cited by 612
O’Brien, P. J., Irwin, W., Diaz, D., Howard-Cofield, E., Krejsa, C. M., Slaughter, M. R., Gao, B., Kaludercic, N., Angeline, A., Bernardi, P., et al. (2006) · Archives of Toxicology · doi:10.1007/s00204-006-0091-3 · Cited by 609
Cellular Imaging Predictions of Clinical Drug-Induced Liver Injury
Xu, J. J., Henstock, P. V., Dunn, M. C., Smith, A. R., Chabot, J. R., & de Graaf, D. (2008) · Toxicological Sciences · doi:10.1093/toxsci/kfn109 · Cited by 492
Obach, R. S., Lombardo, F., & Waters, N. J. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.020479 · Cited by 462
Shitara, Y., Maeda, K., Ikejiri, K., Yoshida, K., Horie, T., & Sugiyama, Y. (2013) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.1823 · Cited by 418
FDA-approved drug labeling for the study of drug-induced liver injury
Chen, M., Vijay, V., Shi, Q., Liu, Z., Fang, H., & Tong, W. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.05.007 · Cited by 406
Lammert, C., Einarsson, S., Saha, C., Niklasson, A., Bjornsson, E., & Chalasani, N. (2008) · Hepatology · doi:10.1002/hep.22272 · Cited by 389
Chen, M., Borlak, J., & Tong, W. (2013) · Hepatology · doi:10.1002/hep.26208 · Cited by 348
Dawson, S., Stahl, S., Paul, N., Barber, J., & Kenna, J. G. (2012) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.040758 · Cited by 343
Morgan, R. E., Trauner, M., van Staden, C. J., Lee, P. H., Ramachandran, B., Eschenberg, M., Afshari, C. A., Qualls, C. W., Lightfoot-Dunn, R., & Hamadeh, H. K. (2010) · Toxicological Sciences · doi:10.1093/toxsci/kfq269 · Cited by 325
Nakayama, S., Atsumi, R., Takakusa, H., Kobayashi, Y., Kurihara, A., Nagai, Y., Nakai, D., & Okazaki, O. (2009) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.027797 · Cited by 251
Morgan, R. E., van Staden, C. J., Chen, Y., Kalyanaraman, N., Kalanzi, J., Dunn, R. T., Afshari, C. A., & Hamadeh, H. K. (2013) · Toxicological Sciences · doi:10.1093/toxsci/kft176 · Cited by 243 · cited 3×
“For example, most-DILI compounds such as nefazodone, troglitazone, benzbromarone with triple liabilities in our analysis are also known to form covalent adducts, are positive for cytotoxicity in a THLE cell line selectively expressing CYP3A4, and are inhibitors of multidrug resistance-associated protein 4 (Morgan et a…”
BackgroundLiverTox: A website on drug-induced liver injury
Hoofnagle, J. H., Serrano, J., Knoben, J. E., & Navarro, V. J. (2013) · Hepatology · doi:10.1002/hep.26175 · Cited by 242
Meier, Y., Pauli-Magnus, C., Zanger, U. M., Klein, K., Schaeffeler, E., Nussler, A. K., Nussler, N., Eichelbaum, M., Meier, P. J., & Stieger, B. (2006) · Hepatology · doi:10.1002/hep.21214 · Cited by 219
Aleo, M. D., Luo, Y., Swiss, R., Bonin, P. D., Potter, D. M., & Will, Y. (2014) · Hepatology · doi:10.1002/hep.27206 · Cited by 215
Self-citationThompson, R. A., Isin, E. M., Li, Y., Weidolf, L., Page, K., Wilson, I., Swallow, S., Middleton, B., Stahl, S., Foster, A. J., et al. (2012) · Chemical Research in Toxicology · doi:10.1021/tx300091x · Cited by 213
Intrinsic versus Idiosyncratic Drug-Induced Hepatotoxicity—Two Villains or One?
Roth, R. A., & Ganey, P. E. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.162651 · Cited by 183
Porceddu, M., Buron, N., Roussel, C., Labbe, G., Fromenty, B., & Borgne-Sanchez, A. (2012) · Toxicological Sciences · doi:10.1093/toxsci/kfs197 · Cited by 181
Usui, T., Mise, M., Hashizume, T., Yabuki, M., & Komuro, S. (2009) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.028860 · Cited by 153
Hynes, J., Marroquin, L. D., Ogurtsov, V. I., Christiansen, K. N., Stevens, G. J., Papkovsky, D. B., & Will, Y. (2006) · Toxicological Sciences · doi:10.1093/toxsci/kfj208 · Cited by 148
Self-citationToward Predictive Models for Drug-Induced Liver Injury in Humans: Are we There Yet?
Chen, M., Bisgin, H., Tong, L., Hong, H., Fang, H., Borlak, J., & Tong, W. (2014) · Biomarkers in Medicine · doi:10.2217/bmm.13.146 · Cited by 136
Holt, M., & Ju, C. (2010) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-642-00663-0_1 · Cited by 129
Kostrubsky, S. E., Strom, S. C., Kalgutkar, A. S., Kulkarni, S., Atherton, J., Mireles, R., Feng, B., Kubik, R., Hanson, J., Urda, E., et al. (2006) · Toxicological Sciences · doi:10.1093/toxsci/kfj095 · Cited by 121
Chen, M., Hong, H., Fang, H., Kelly, R., Zhou, G., Borlak, J., & Tong, W. (2013) · Toxicological Sciences · doi:10.1093/toxsci/kft189 · Cited by 115
Rodrigues, A. D., Lai, Y., Cvijic, M. E., Elkin, L. L., Zvyaga, T. A., & Soars, M. G. (2013) · Drug Metabolism and Disposition · doi:10.1124/dmd.113.054205 · Cited by 113
Self-citationKelly, R. P., Garhyan, P., Raddad, E., Fu, H., Lim, C. N., Prince, M. J., Pinaire, J. A., Loh, M. T., & Deeg, M. A. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12446 · Cited by 110 · cited 3×
“In addition, LY-2409021 had a safety margin of 0.58-fold in THLE cytotoxicity and 1.9-fold in mitochondrial uncoupling assay.”
BackgroundInfluentialLee, E.-W., Lai, Y., Zhang, H., & Unadkat, J. D. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m513825200 · Cited by 109
Howell, B. A., Yang, Y., Kumar, R., Woodhead, J. L., Harrill, A. H., M.A., H. J. C. I., Andersen, M. E., Siler, S. Q., & Watkins, P. B. (2012) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-012-9266-0 · Cited by 107
Yang, K., Woodhead, J. L., Watkins, P. B., Howell, B. A., & Brouwer, K. L. R. (2014) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2014.158 · Cited by 95
Exploring BSEP inhibition-mediated toxicity with a mechanistic model of drug-induced liver injury
Woodhead, J. L., Yang, K., Siler, S. Q., Watkins, P. B., Brouwer, K. L. R., Barton, H. A., & Howell, B. A. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00240 · Cited by 93
Self-citationLeifke, E., Naik, H., Wu, J., Viswanathan, P., DeManno, D., Kipnes, M., & Vakilynejad, M. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.43 · Cited by 88
Hynes, J., Nadanaciva, S., Swiss, R. L., Carey, C., Kirwan, S., & Will, Y. (2012) · Toxicology in Vitro · doi:10.1016/j.tiv.2012.11.002 · Cited by 83
Self-citationFeng, B., Xu, J. J., Bi, Y.-A., Mireles, R., Davidson, R., Duignan, D. B., Campbell, S., Kostrubsky, V. E., Dunn, M. C., Smith, A. R., et al. (2009) · Toxicological Sciences · doi:10.1093/toxsci/kfp033 · Cited by 80
Using an in vitro cytotoxicity assay to aid in compound selection for in vivo safety studies
Greene, N., Aleo, M. D., Louise‐May, S., Price, D. A., & Will, Y. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.06.129 · Cited by 69
Self-citationNefazodone (Serzone) withdrawn because of hepatotoxicity.
Choi, S. (2003) · Europe PMC (PubMed Central) · Cited by 68
Pharmacokinetic evaluation of desogestrel as a female contraceptive
Grandi, G., Cagnacci, A., & Volpe, A. (2014) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2013.844229 · Cited by 54
Analysis of Pfizer Compounds in EPA’s ToxCast Chemicals-Assay Space
Shah, F., & Greene, N. (2014) · Chemical Research in Toxicology · doi:10.1021/tx400343t · Cited by 47
Self-citationWager, T. T., Kormos, B. L., Brady, J. T., Will, Y., Aleo, M. D., Stedman, D. B., Kuhn, M., & Chandrasekaran, R. Y. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm401485p · Cited by 42
Self-citationShah, F., Louise‐May, S., & Greene, N. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.04.039 · Cited by 27
Self-citationPredictingIn VivoSafety Characteristics Using Physiochemical Properties andIn VitroAssays
Greene, N., & Song, M. (2011) · Future Medicinal Chemistry · doi:10.4155/fmc.11.89 · Cited by 12
Self-citationMechanisms of Drug Hepatotoxicity in Man: Novel Insights Provided by the THLE-CYP Cell Panel
Greer, M. L., Smith, T. J. D., & Kenna, J. G. (2009) · Toxicology · doi:10.1016/j.tox.2009.04.047 · Cited by 9
Research works printed but not linked: 1
- Ruddy, 2011, Inhibition of glucagon-induced hyperglycemia predicts glucose lowering efficacy of a glucagon receptor antagonist, MK-0893, in type 2 diabetes (T2DM) [Abstract], Diabetes, 60, A85
Cited by
Drugging the NLRP3 inflammasome: from signalling mechanisms to therapeutic targets
Vande Walle, L., & Lamkanfi, M. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00822-2 · Cited by 350
Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury
Proctor, W. R., Foster, A. J., Vogt, J., Summers, C., Middleton, B., Pilling, M. A., Shienson, D., Kijanska, M., Ströbel, S., Kelm, J. M., et al. (2017) · Archives of Toxicology · doi:10.1007/s00204-017-2002-1 · Cited by 328
“Statistical analysis employing ROC assessments Dose and drug exposure, as measured by the total plasma Cmax levels, has been shown to be associated with DILI (Chen et al. 2013; Shah et al. 2015).”
BackgroundMethodInfluentialBaudy, A. R., Otieno, M. A., Hewitt, P., Gan, J., Roth, A., Keller, D., Sura, R., Van Vleet, T. R., & Proctor, W. R. (2020) · Lab on a Chip · doi:10.1039/c9lc00768g · Cited by 150
A critical perspective on 3D liver models for drug metabolism and toxicology studies
Serras, A. S., Rodrigues, J. S., Cipriano, M., Rodrigues, A. V., Oliveira, N. G., & Miranda, J. P. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.626805 · Cited by 138
Self-citationPredicting Drug-Induced Liver Injury with Bayesian Machine Learning
Williams, D. P., Lazic, S. E., Foster, A. J., Semenova, E., & Morgan, P. (2020) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.9b00264 · Cited by 124
Metadata
- Authors
- Shah, F., Leung, L., Barton, H. A., Will, Y., Rodrigues, A. D., Greene, N., & Aleo, M. D.
- Affiliations
- Pfizer (United States) (US)
- Venue
- Toxicological Sciences
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-07-23
- Volume
- 147
- Issue
- 2
- Pages
- 500-514
- ISSN
- 1096-0929 (ISSN-L)
- 1096-6080
- OpenAlex
- W2140427118
- Cited by
- 148
- References
- 46
- Citations by year
- 2026: 13 · 2025: 18 · 2024: 18 · 2023: 10 · 2022: 10 · 2021: 10 · 2020: 18 · 2019: 10 · 2018: 11 · 2017: 16 · 2016: 11 · 2015: 3
- FWCI
- 15.91
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Toxicological Sciences (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Health Sciences › Veterinary › Small Animals › Animal testing and alternatives
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- drug-induced liver injury, hepatotoxicity prediction, mitochondrial inhibition, mitochondrial uncoupling, cytotoxicity, drug safety, drug repurposing
- MeSH terms
- Humans, Maximum Allowable Concentration, Retrospective Studies, Toxicity Tests, Inhibitory Concentration 50, Chemical and Drug Induced Liver Injury, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.